Table 3.
Statement | Agree | Disagree | Not Sure/I Don’t Know | Positive Shift | Negative Shift | p | |||
---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | ||||
COVID-19 Is a Serious Disease | |||||||||
Males | |||||||||
Before | 123 | 69.9 | 35 | 19.9 | 18 | 10.2 | |||
After | 143 | 81.3 | 22 | 12.5 | 11 | 6.3 | |||
Difference | 20 | 16% | −13 | −37% | −7 | −39% | 18% | 4% | <0.0001 |
Females | |||||||||
Before | 258 | 75.4 | 48 | 14.0 | 36 | 10.5 | |||
After | 304 | 88.9 | 15 | 4.4 | 23 | 6.7 | |||
Difference | 46 | 18% | −33 | −69% | −13 | −36% | 19% | 5% | <0.0001 |
<250,000 | |||||||||
Before | 269 | 74.1 | 69 | 19.0 | 25 | 6.9 | |||
After | 315 | 83.8 | 36 | 9.6 | 25 | 6.6 | |||
Difference | 46 | 13% | −33 | −50% | 0 | −3% | 19% | 6% | <0.0001 |
≥250,000 | |||||||||
Before | 112 | 78.9 | 14 | 9.9 | 16 | 11.3 | |||
After | 132 | 93.0 | 1 | 0.7 | 9 | 6.3 | |||
Difference | 20 | 18% | −13 | −93% | −7 | −44% | 18% | 0% | <0.0001 |
Life science | |||||||||
Before | 288 | 76.6 | 51 | 13.6 | 37 | 9.8 | |||
After | 339 | 90.2 | 17 | 4.5 | 20 | 5.3 | |||
Difference | 51 | 18% | −34 | −67% | −17 | −46% | 18% | 2% | <0.0001 |
Other | |||||||||
Before | 93 | 65.5 | 32 | 22.5 | 17 | 12.0 | |||
After | 108 | 76.1 | 20 | 14.1 | 14 | 9.9 | |||
Difference | 15 | 16% | −12 | −38% | −3 | −18% | 20% | 8% | 0.002 |
COVID-19 Doesn’t Concern Me | |||||||||
Males | |||||||||
Before | 30 | 17.0 | 125 | 71,0 | 21 | 11.9 | |||
After | 20 | 11.4 | 146 | 83.0 | 10 | 5.7 | |||
Difference | −10 | −33% | 21 | 17% | −11 | −52% | 20% | 8% | 0.0001 |
Females | |||||||||
Before | 34 | 9.9 | 251 | 73.4 | 57 | 16.7 | |||
After | 32 | 9.4 | 285 | 83.3 | 25 | 7.3 | |||
Difference | −2 | −6% | 34 | 14% | −32 | −56% | 20% | 16% | <0.0001 |
<250,000 | |||||||||
Before | 56 | 14.9 | 259 | 68.9 | 61 | 16.2 | |||
After | 46 | 12.2 | 301 | 80.1 | 29 | 7.7 | |||
Difference | −10 | −18% | 42 | 16% | −32 | −52% | 22% | 14% | <0.0001 |
≥250,000 | |||||||||
Before | 8 | 5.6 | 117 | 8.4 | 17 | 12.0 | |||
After | 6 | 4.2 | 130 | 91.5 | 6 | 4.2 | |||
Difference | −2 | −25% | 13 | 11% | −11 | −65% | 14% | 12% | 0.003 |
Life science | |||||||||
Before | 35 | 9.3 | 288 | 76.6 | 53 | 14.1 | |||
After | 30 | 8.0 | 324 | 86.2 | 22 | 5.9 | |||
Difference | −5 | −14% | 36 | 13% | −31 | −58% | 31% | 9% | <0.0001 |
Other | |||||||||
Before | 29 | 20.4 | 88 | 62.0 | 25 | 17.6 | |||
After | 22 | 15.5 | 107 | 75.4 | 13 | 9.2 | |||
Difference | −7 | −24% | 19 | 22% | −12 | −48% | 53% | 20% | 0.001 |
I Am Concerned My Parents Will Contract COVID-19 | |||||||||
Males | |||||||||
Before | 65 | 36.9 | 85 | 48.3 | 26 | 14.8 | |||
After | 95 | 54.0 | 63 | 35.8 | 18 | 10.2 | |||
Difference | 30 | 46% | −22 | −26% | −8 | −31% | 51% | 3% | <0.0001 |
Females | |||||||||
Before | 167 | 48.8 | 129 | 37.7 | 46 | 13.5 | |||
After | 210 | 61.4 | 93 | 27.2 | 39 | 11.4 | |||
Difference | 43 | 26% | −36 | −28% | −7 | −15% | 27% | 1% | <0.0001 |
<250,000 | |||||||||
Before | 155 | 41.2 | 165 | 43.9 | 56 | 14.9 | |||
After | 198 | 52.7 | 131 | 34.8 | 47 | 12.5 | |||
Difference | 43 | 28% | −34 | −21% | −9 | −16% | 31% | 2% | <0.0001 |
≥250,000 | |||||||||
Before | 77 | 54.2 | 49 | 34.5 | 16 | 11.3 | |||
After | 107 | 75.4 | 25 | 17.6 | 10 | 7.0 | |||
Difference | 30 | 39% | −24 | −49% | −6 | −38% | 39% | 0% | <0.0001 |
Life science | |||||||||
Before | 183 | 48.7 | 139 | 37.0 | 54 | 14.4 | |||
After | 240 | 63.8 | 98 | 26,1 | 38 | 10.1 | |||
Difference | 57 | 31% | −41 | −29% | −16 | −30% | 32% | 1% | <0.0001 |
Other | |||||||||
Before | 49 | 34.5 | 75 | 52.8 | 18 | 12.7 | |||
After | 65 | 45.8 | 58 | 40.8 | 19 | 13.4 | |||
Difference | 16 | 33% | −17 | −23% | 1 | 6% | 39% | 3% | 0.0007 |
I Am Concerned My Grandparents Will Contract COVID-19 | |||||||||
Males | |||||||||
Before | 93 | 52.8 | 66 | 37.5 | 17 | 9.7 | |||
After | 109 | 61.9 | 51 | 29.0 | 16 | 9.1 | |||
Difference | 16 | 17% | −15 | −23% | −1 | −6% | 19% | 2% | 0.0004 |
Females | |||||||||
Before | 210 | 61.4 | 96 | 28.1 | 36 | 10.5 | |||
After | 241 | 70.5 | 73 | 21.3 | 28 | 8.2 | |||
Difference | 31 | 15% | −23 | −24% | −8 | −22% | 17% | 4% | <0.0001 |
<250,000 | |||||||||
Before | 203 | 54.0 | 128 | 34.0 | 45 | 12.0 | |||
After | 237 | 63.0 | 99 | 26.3 | 40 | 10.6 | |||
Difference | 34 | 17% | −29 | −23% | −5 | −11% | 20% | 3% | <0.0001 |
≥250,000 | |||||||||
Before | 100 | 70.4 | 34 | 23.9 | 8 | 5.6 | |||
After | 113 | 79.6 | 25 | 17.6 | 4 | 2.8 | |||
Difference | 13 | 13% | −9 | −26% | −4 | −50% | 14% | 2% | 0.0009 |
Life science | |||||||||
Before | 238 | 63.3 | 102 | 27.1 | 36 | 9.6 | |||
After | 272 | 72.3 | 74 | 19.7 | 30 | 8.0 | |||
Difference | 34 | 14% | −28 | −27% | −6 | −17% | 16% | 4% | <0.0001 |
Other | |||||||||
Before | 65 | 45.8 | 60 | 42.3 | 17 | 12.0 | |||
After | 78 | 54.9 | 50 | 35.2 | 14 | 9.9 | |||
Difference | 13 | 20% | −10 | −17% | −3 | −18% | 23% | 3% | 0.002 |
Reporting Suspected COVID-19 Cases to the Health Authorities Is Crucial to Combat the Epidemic | |||||||||
Males | |||||||||
Before | 139 | 79.0 | 20 | 11.4 | 17 | 9.7 | |||
After | 150 | 85.2 | 15 | 8.5 | 11 | 6.3 | |||
Difference | 11 | 8% | −5 | −25% | −6 | −35% | 12% | 14% | <0.0001 |
Females | |||||||||
Before | 260 | 76.0 | 18 | 5.3 | 64 | 18.7 | |||
After | 300 | 87.7 | 11 | 3.2 | 31 | 9.1 | |||
Difference | 40 | 15% | −7 | −39% | −33 | −52% | 17% | 5% | 0.02 |
<250,000 | |||||||||
Before | 279 | 74.2 | 34 | 9.0 | 63 | 16.8 | |||
After | 315 | 83.8 | 25 | 6.6 | 36 | 9.6 | |||
Difference | 36 | 13% | −9 | −26% | −27 | −43% | 16% | 9% | <0.0001 |
≥250,000 | |||||||||
Before | 120 | 84.5 | 4 | 2.8 | 18 | 12.7 | |||
After | 135 | 95.1 | 1 | 0.7 | 6 | 4.2 | |||
Difference | 15 | 13% | −3 | −75% | −12 | −67% | 13% | 0% | 0.0001 |
Life science | |||||||||
Before | 302 | 80.3 | 22 | 5.9 | 52 | 13.8 | |||
After | 339 | 90.2 | 12 | 3.2 | 25 | 6.6 | |||
Difference | 37 | 12% | −10 | −45% | −27 | −52% | 13% | 4% | <0.0001 |
Other | |||||||||
Before | 97 | 68.3 | 16 | 11.3 | 29 | 20.4 | |||
After | 111 | 78.2 | 14 | 9.9 | 17 | 12.0 | |||
Difference | 14 | 14% | −2 | −13% | −12 | −41% | 21% | 13% | 0.006 |
It Is Important to Use Face Masks in Crowded Places to Minimize the Risk of SARS-CoV-2 Infection | |||||||||
Males | |||||||||
Before | 140 | 79.5 | 23 | 13.1 | 13 | 7.4 | |||
After | 151 | 85.8 | 18 | 10.2 | 7 | 4.0 | |||
Difference | 11 | 8% | −5 | −22% | −6 | −46% | 11% | 14% | 0.02 |
Females | |||||||||
Before | 268 | 78.4 | 35 | 10.2 | 39 | 11.4 | |||
After | 310 | 90.6 | 17 | 5.0 | 15 | 4.4 | |||
Difference | 42 | 16% | −18 | −51% | −24 | −62% | 18% | 7% | <0.0001 |
<250,000 | |||||||||
Before | 280 | 74.5 | 54 | 14.4 | 42 | 11.2 | |||
After | 322 | 85.6 | 34 | 9.0 | 20 | 5.3 | |||
Difference | 42 | 15% | −20 | −37% | −22 | −52% | 19% | 10% | <0.0001 |
≥250,000 | |||||||||
Before | 128 | 90.1 | 4 | 2.8 | 10 | 7.0 | |||
After | 139 | 97.9 | 1 | 0.7 | 2 | 1.4 | |||
Difference | 11 | 9% | −3 | −75% | −8 | −80% | 9% | 0% | 0.001 |
Life science | |||||||||
Before | 310 | 82.4 | 30 | 8.0 | 36 | 9.6 | |||
After | 349 | 92.8 | 16 | 4.3 | 11 | 2.9 | |||
Difference | 39 | 13% | −14 | −47% | −25 | −69% | 14% | 8% | <0.0001 |
Other | |||||||||
Before | 98 | 69.0 | 28 | 19.7 | 16 | 11.3 | |||
After | 112 | 78.9 | 19 | 13.4 | 11 | 7.7 | |||
Difference | 14 | 14% | −9 | −32% | −5 | −31% | 19% | 11% | 0.004 |
It Is Important to Wash Our Hands Often to Prevent the SARS-CoV-2 Infection | |||||||||
Males | |||||||||
Before | 158 | 89.8 | 10 | 5.7 | 8 | 4.5 | |||
After | 161 | 91.5 | 11 | 6.3 | 4 | 2.3 | |||
Difference | 3 | 2% | 1 | 10% | −4 | −50% | 6% | 33% | 0.46 |
Females | |||||||||
Before | 330 | 96.5 | 4 | 1.2 | 8 | 2.3 | |||
After | 335 | 98.0 | 0 | 0.0 | 7 | 2.0 | |||
Difference | 5 | 2% | −4 | −100% | −1 | −13% | 2% | 25% | 0.15 |
<250,000 | |||||||||
Before | 349 | 92.8 | 12 | 3.2 | 15 | 4.0 | |||
After | 357 | 94.9 | 10 | 2.7 | 9 | 2.4 | |||
Difference | 8 | 2% | −2 | −17% | −6 | −40% | 5% | 30% | 0.11 |
≥250,000 | |||||||||
Before | 139 | 97.9 | 2 | 1.4 | 1 | 0.7 | |||
After | 139 | 97.9 | 1 | 0.7 | 2 | 1.4 | |||
Difference | 0 | 0% | −1 | −50% | 1 | 100% | 1% | 33% | 0.64 |
Life science | |||||||||
Before | 357 | 94.9 | 8 | 2.1 | 11 | 2.9 | |||
After | 364 | 96.8 | 6 | 1.6 | 6 | 1.6 | |||
Difference | 7 | 2% | −2 | −25% | −5 | −45% | 3% | 21% | 0.08 |
Other | |||||||||
Before | 131 | 92.3 | 6 | 4.2 | 5 | 3.5 | |||
After | 132 | 93.0 | 5 | 3.5 | 5 | 3.5 | |||
Difference | 1 | 1% | −1 | −17% | 0 | 0% | 5% | 45% | 0.80 |
COVID-19 Is a Preventable Disease | |||||||||
Males | |||||||||
Before | 114 | 64.8 | 26 | 14.8 | 36 | 20.5 | |||
After | 128 | 72.7 | 17 | 9.7 | 31 | 17.6 | |||
Difference | 14 | 12% | −9 | −35% | −5 | −14% | 25% | 24% | 0.04 |
Females | |||||||||
Before | 188 | 55.0 | 54 | 15.8 | 100 | 29.2 | |||
After | 228 | 66.7 | 33 | 9.6 | 81 | 23.7 | |||
Difference | 40 | 21% | −21 | −39% | −19 | −19% | 36% | 18% | <0.0001 |
<250,000 | |||||||||
Before | 227 | 60.4 | 57 | 15.2 | 92 | 24.5 | |||
After | 250 | 66.5 | 42 | 11.2 | 84 | 22.3 | |||
Difference | 23 | 10% | −15 | −26% | −8 | −9% | 26% | 25% | 0.02 |
≥250,000 | |||||||||
Before | 75 | 52.8 | 23 | 16.2 | 44 | 31.0 | |||
After | 106 | 74.6 | 8 | 5.6 | 28 | 19.7 | |||
Difference | 31 | 41% | −15 | −65% | −16 | −36% | 49% | 9% | <0.0001 |
Life science | |||||||||
Before | 217 | 57.7 | 54 | 14.4 | 105 | 27.9 | |||
After | 262 | 69.7 | 30 | 8.0 | 84 | 22.3 | |||
Difference | 45 | 21% | −24 | −44% | −21 | −20% | 33% | 17% | <0.0001 |
Other | |||||||||
Before | 85 | 59.9 | 26 | 18.3 | 31 | 21.8 | |||
After | 94 | 66.2 | 20 | 14.1 | 28 | 19.7 | |||
Difference | 9 | 11% | −6 | −23% | −3 | −10% | 29% | 28% | 0.16 |
Health Education Has a Significant Impact on COVID-19 Prevention and Control | |||||||||
Males | |||||||||
Before | 140 | 79.5 | 13 | 7.4 | 23 | 13.1 | |||
After | 156 | 88.6 | 8 | 4.5 | 12 | 6.8 | |||
Difference | 16 | 11% | −5 | −38% | −11 | −48% | 14% | 11% | 0.001 |
Females | |||||||||
Before | 284 | 83.0 | 24 | 7.0 | 34 | 9.9 | |||
After | 301 | 88.0 | 10 | 2.9 | 31 | 9.1 | |||
Difference | 17 | 6% | −14 | −58% | −3 | −9% | 9% | 16% | 0.004 |
<250,000 | |||||||||
Before | 290 | 77.1 | 36 | 9.6 | 50 | 13.3 | |||
After | 320 | 85.1 | 17 | 4.5 | 39 | 10.4 | |||
Difference | 30 | 10% | −19 | −53% | −11 | −22% | 14% | 14% | <0.0001 |
≥250,000 | |||||||||
Before | 134 | 94,4 | 1 | 0,7 | 7 | 4,9 | |||
After | 137 | 96,5 | 1 | 0,7 | 4 | 2,8 | |||
Difference | 3 | 2% | 0 | 0% | −3 | −43% | 3% | 13% | 0.23 |
Life science | |||||||||
Before | 323 | 85.9 | 18 | 4.8 | 35 | 9.3 | |||
After | 345 | 91.8 | 8 | 2.1 | 23 | 6.1 | |||
Difference | 22 | 7% | −10 | −56% | −12 | −34% | 8% | 9% | 0.0001 |
Other | |||||||||
Before | 101 | 71.1 | 19 | 13.4 | 22 | 15.5 | |||
After | 112 | 78.9 | 10 | 7.0 | 20 | 14.1 | |||
Difference | 11 | 11% | −9 | −47% | −2 | −9% | 19% | 20% | 0.03 |
I Would Vaccinate Myself against SARS-CoV-2 if a Vaccine Was Available | |||||||||
Males | |||||||||
Before | 106 | 60.2 | 32 | 18.2 | 38 | 21.6 | |||
After | 110 | 62.5 | 29 | 16.5 | 37 | 21.0 | |||
Difference | 4 | 4% | −3 | −9% | −1 | −3% | 11% | 11% | 0.38 |
Females | |||||||||
Before | 168 | 49.1 | 77 | 22.5 | 97 | 28.4 | |||
After | 182 | 53.2 | 64 | 18.7 | 96 | 28.1 | |||
Difference | 14 | 8% | −13 | −17% | −1 | −1% | 11% | 3% | 0.004 |
<250.000 | |||||||||
Before | 176 | 46.8 | 95 | 25.3 | 105 | 27.9 | |||
After | 185 | 49.2 | 85 | 22.6 | 106 | 28.2 | |||
Difference | 9 | 5% | −10 | −11% | 1 | 1% | 13% | 7% | 0.13 |
≥250.000 | |||||||||
Before | 98 | 69.0 | 14 | 9.9 | 30 | 21.1 | |||
After | 107 | 75.4 | 8 | 5.6 | 27 | 19.0 | |||
Difference | 9 | 9% | −6 | −43% | −3 | −10% | 9% | 0% | 0.003 |
Life science | |||||||||
Before | 208 | 55.3 | 66 | 17.6 | 102 | 27.1 | |||
After | 228 | 60.6 | 53 | 14.1 | 95 | 25.3 | |||
Difference | 20 | 10% | −13 | −20% | −7 | −7% | 12% | 3% | 0.0003 |
Other | |||||||||
Before | 66 | 46.5 | 43 | 30.3 | 33 | 23.2 | |||
After | 64 | 45.1 | 40 | 28.2 | 38 | 26.8 | |||
Difference | −2 | −3% | −3 | −7% | 5 | 15% | 9% | 11% | 0.62 |